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PALINDROMIC RHEUMATISM, SYSTEMIC LUPUS ERYTHEMATOSUS,
AND CIRCULATING ANTICOAGULANT ACTIVITY
HOWARD DUNCAN, M.D.* AND E L L I S J. V . \ N SLYCK, M.D.**

Dr. Howard Duncan: This morning's patient, an old friend of the hospital, had
been perfectly well and attending the clinic for his "annual physical" since 1957.
Now aged 53, Mr. K. is an executive at one of the motor companies. In 1946, at
his discharge from the Army, he was said to have had a trace of albumin in the
urine. 1961 we noted a slight trace of albumin as the only abnormality. The test
was repeated and was negative. In 1963 and 1964 the urine was not abnormal,
but at the latter examination the patient complained of some discomfort in the joint
areas which he could always relate to a heavy game of golf or to excessive activity
in the garden. It involved various joints individually, a finger, a wrist, an elbow,
but was never severe enough to incapacitate the patient nor to keep him off work
even though his job called for walking many miles in daily inspections. There was
no family history of joint disease or illness of any sort. In 1965, Dr. Joseph Szokolay,
who had been following the patient, made the diagnosis of pahndromic rheumatism.
In January 1966 Mr. K. remarked to Dr. Szokolay that the discomfort, which
usually had lasted less than 48 hours, was a little more prolonged with a few
extra joints involved. At physical examination, a palpably enlarged spleen was detected
for the first time. In addition, the patient had noted an occasional, evanescent discomfort in a toe or a finger at the site of a small skin lesion which resembled a
tiny spider, of the type we see in advanced liver disease. The patient also showed
a painful great toe with faint blue mottling and attended by numbness which would
last for only a day or two.
Among the laboratory tests, the hemoglobin was 11.3 grams (a drop of 4 grams
which I think is probably at least two standard deviations outside the laboratory error)
and a WBC of 5100; the urine contained red cells, casts, and again a trace of albumin.
With these somewhat disjointed findings, we decided to admit the patient to the
hospital for further evaluation.
* Division of Rheumatology.
**Division of Hematology.
Abridged transcript of Tuesday Morning Medical Conference edited by W. S. Haubrich, M.D.
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In my view, the patient gave as classical a story of palindromic rheumatism
as one could expect, i.e., the sudden onset of pain in a joint without specific
provocation. The peculiarity of this syndrome is that it lasts for less than 48 hours
and is recurrent. Initially, it has to be differentiated from gout or acute cellulitis. It
can simulate both, but usually by the time the patient comes for examination the
pain and swelling have disappeared and you then begin to wonder whether the
patient is a reliable observer.
Because palindromic rheumatism produces sudden, transient changes, it was my
lot, when working with Dr. E. G. L. Bywaters in London, to be available in the
hospital during the night to evaluate people who arrived complaining of episodic
arthritis. The acute reaction would be visible and only the normal uric acid, the
negative latex fixation and the short duration of the symptoms would distinguish
palindromic rheumatism from other episodic types of joint disease.
The long-term prognosis is also a distinguishing feature. The late Dr. Philip
Hench of the Mayo Clinic defined the syndrome as one that did not convert to any
other illness and left no residual deformity. Thus, if we follow these patients for
20 years or more, about 50% will not have any other pattern or suffer any permanent
change in the joint area. However, in the remaining half rheumatoid arthritis develops,
or even more rarely, systemic lupus erythematosus.
To return to this morning's patient, it was an increasing persistence of
the joint pains that aroused our suspicion, in addition to the intermittent albuminuria and the newly apparent splenomegaly. In the hospital, repeated urine
cultures failed to yield pathogenic organisms. The serum urea nitrogen and serum
creatinine were normal. Significantly, however, the serum gamma globulin was 2.2
grams per 100 ml. Two LE cell preparations were negative although two determinations of antinuclear factor showed strong homogeneous fluorescence. The patient's
prothrombin time was 22 seconds against a control of 14. These were the first
evidences that we were running into bigger trouble than anticipated. I can confess
that the patient's ultimate diagnosis of systemic lupus erythematosus had not been
seriously entertained for I knew of no reported case in which there had been such
a clear-cut presentation with palindromic rheumatism.
I will ask Dr. Van Slyck to tell us of his significant hematologic investigations.
Dr. Ellis Van Slyck: I will review with you this morning the results of coagulation
studies done on Mr. K. We do many of these studies on any patient under consideration for a renal biopsy, and in this case serendipity was present. I wonder if
this patient's diagnosis, or at least this feature of the diagnosis, would have been
made, had he not been considered for a renal biopsy. The test results are seen in
Tables I and I I . The tourniquet test was 3-|-, which we consider of significance as
evidence of vascular fragility or platelet functional defect. Since we were concomitantly
aware that this man had a significantly low platelet count (20,000), we felt this
250

PALINDROMIC

RHEUMATISM

Table I
COAGULATION STUDIES
Normal

Patient

Tourniquet Test

O-l-b

3+

Clotting Time
(Lee-White 2 tube)

< 12 min.

20 & 25 min.

Plasma Clotting Time

90-150 sec.

510 sec.

Prothrombin Time

14 sec.

20 sec.

Prothrombin Consumption

> 30 sec.

Partial Thromboplastin Time

57 sec.

196 sec.

Platelet Count

> 250,000/mm3

20,000/nn-n3

Fibrinolysis

16 sec.

Negative

Results of laboratory tests on Mr. K. #87 15 26, done on January 26, 1966, with normal values for
comparison.

was simply a manifestation of thrombocytopenia. However, the whole blood clotting
time of 20 and 25 minutes (Lee-White 2 tube method) is a rather unusual finding
in patients without a history suggesting hemophilia, so it aroused our interest.
The plasma clotting time is a test which tends to bring out any significant
disorder in the intrinsic activating system of prothrombin conversion and, as we can
see here, this man has a value of 510 seconds compared to the normal of between
90 and 150 seconds. This represents a striking prolongation. The prothrombin time
done in the coa.gulation laboratory was not 22, but 20 seconds. This test is, in the
coagulation sphere at least, a measure of the integrity of the extrinsic activating
system generally, and of factor V I I in particular. The prothrombin consumption is
a somewhat general screening test for coagulation disorders; it doesn't pinpoint the
specific factor involved. In fact, defective platelet factor 3 activity in the intrinsic
system causes a disorder of the prothrombin consumption, in addition to deficiencies
of any of the other intrinsic factors. In this instance, the result of 16 seconds is
definitely abnormal, in the range where we find most hemophiliacs. Fibrinolytic
activity was looked for and was not found.
The partial thromboplastin test is another good method for picking up disorders
in the intrinsic activating system which includes factors X I I , X I , IX, V I I I , X, and V
(in their chronological order of activity). In this test, platelet number or platelet
factor 3 activity does not influence the result; in other words, the abnormal result
seen here is not due to this patient's low platelet count, but presumably to an
interference with or a lack of one or more of the other factors. The two-stage
prothrombin assay (Table 2) measures the integrity of the extrinsic activating system.
We see that the abnormal result in the patient's plasma is not appreciably corrected
by the addition of Ac-globulin (factor V ) . Comparison with the control plasma
is rather striking. In addition, note that there is a residual of 50 units of prothrombin
in the patient's serum, which normally should be less than one tenth of that in the
plasma.
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Table 11
COAGULATION STUDIES (Con't.)
Two Stage Prothrombin Assay
Control Plasma

291 units/ml

Patient Plasma s AcG. added

136 units/ml

Patient Plasma c AcG. added

I 4 | units/ml

Patient Serum

50 units/ml

Test For Circulating Anticoagulant Using Plasma Clotting Time
Control

96 sec.

Patient

49O sec.

1 part patient + 1 part control

310 sec.

1 part patient -I- 2 parts control

310 sec.

1 part patient -I- 10 parts control

230 sec.

Results of additional coagulation studies on Mr. K. #87 15 26, done on January 29, 1966, including
a plasma mixing test to demonstrate a circulating anticoagulant.

Trying to put this all together, we realized that we had evidence, not only of
abnormalities connected with low platelets and failure of platelet factor 3 to contribute
to the coagulation, but also that the extrinsic and intrinsic systems were defective.
This naturally raised the suspicion of the presence of a circulating anticoagulant.
Accordingly, we did an additional simple study (Table 2). The control plasma
clotting time was within the normal range of 96 seconds. The patient's was again
longer than eight minutes. When we added the patient's plasma to an equal part
of the control, there was still a grossly abnormal result. In fact, when only one
part of the patient's plasma was added to 10 parts of the control, the result was
still more than twice normal — clear-cut evidence that the patient's blood contains
an inhibitor of coagulation, or, in other words, a circulating anticoagulant.
Table 3 subclassifies naturally-occurring anticoagulants and draws heavily, as
do the remainder of my remarks, from an excellent recent book by Hardisty and
Ingram.' Naturally occurring anticoagulants can be inhibitors or inactivators. Inhibitors
are substances which interfere with coagulation immediately on testino, such as
in the case we are dealing with this morning. An inactivator is a substance such as
fibrinolysin which destroys a specific procoagulant factor, and, therefore, interferes
wilh coagulation in a progressive manner.
Table I I I
CIRCULATING ANTICOAGULANTS
1. Antithrombins.
2. Heparin-like substances.
3. Specific inhibitors of clotting factors (e.g., factors V I I I , I X ) .
4. Inhibitors of coagulation in SLE
5. Dysproteinemia, as inhibitor of clotting mechanism.
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The anticoagulant described in most cases of lupus erythematosis (there does
not seem to be much question now that Mr. K. has lupus) is a unique anticoagulant
of the inhibitor class. No other circulating anticoagulant behaves exactly like it, and
Mr. K.'s represents a typical example. In the first place, all the tests that were
done here f i t perfectly with those previously reported. Secondly, the association of
this anticoagulant with thrombocytopenia is quite common. The presence of a false
positive serology is often found. I don't believe this is true of Mr. K., but he did
have a positive Coombs' test which is frequently found, as well as the presence of
antinuclear factor and LE cells. No one is sure how this anticoagulant operates in the
coagulation system, i.e. where the inhibition occurs. Ratnoff^ feels that it acts predominantly in the extrinsic system, interfering with the interaction of factors X and V,
while Biggs^ feels that it interferes with the action of factors IX and V I I I in the
intrinsic system.
Be that as it may, these patients, surprisingly, do not have serious bleeding
problems. You might expect them, judging from their laboratory tests, to behave like
hemophiliacs with massive hematuria, hemarthrosis, epistaxis, etc., but such patients
go for long periods of time without problems. If they do have bleeding, it is generally
of a thrombocytopenic type, due to the associated thrombocytopenia to which I have
just alluded. Our patient this morning did have petechiae on the lower extremities,
but this is the only clinical manifestation of a bleeding disorder. There have been
only about 40 cases reported of this unique anticoagulant in lupus. Although one
observer, Margolius," in a review of four series of lupus cases, totaling 107, found
a circulating anticoagulant in 12% of the patients, it is a rare complication.
Another test done on Mr. K. has considerable practical interest, because occasionally a heparin-like substance is found in lupus. The anticoagulant we are
dealing with is not a heparin-like substance, but if it were, it should be possible to
titrate this substance with protamine and presumably ameliorate the condition. However, an in vitro protamine titration on our patient's blood demonstrated no correction
of the inhibitory action of the anticoagulant.
Brief mention of the other types of naturally occurring circulating anticoagulants
is perhaps in order. As a group, they are very rare disorders. The antithrombins
consist of a variable group of substances that have been described under the general
heading of any material which progressively deteriorates thrombin after the clot has
been formed. Fibrin falls into this group since fibrin seems to bind thrombin as it
forms; heparin co-factor is also an antithrombin. Isolated reports of other unique
antithrombins have appeared in the last decade.
Heparin-like substances have been described in a number of conditions: 1) systemic
mast cell disease with a liberation of excessive heparin-like material into the circulation,
2) transient heparinemia associated with the defibrination syndrome, 3) chronic
nephritis, and 4) systemic lupus, as previously mentioned.
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Specific inactivators of coagulation factors occurring in classical hemophilia and
Christmas disease (i.e. factors V I I I and I X respectively) are well known. Occasionally,
they account for refractoriness to replacement therapy, but it should be stressed that
most refractory hemophiliacs do not have a demonstrable inactivator, other causes
being at fault. Less well-known and less common is the appearance of a factor V I I I
inactivator in previously healthy women within two months to a year after childbirth,
with an attendant bleeding diathesis. The cause is unknown. No direct evidence
that this is an antibody related to an immunological difference between maternal
and fetal factor V I I I is available, and the delay in its appearance postpartum does
not fit this type of mechanism. Factor V I I I deficiency due to an inactivator has
also been described after penicillin reactions, in patients with pemphigus, rheumatoid
arthritis, and rheumatic heart disease, but obviously it is a very rare type of disorder.
There is just time to mention that in the dysproteinemias, the abnormal globulin
may operate as an inhibitor of coagulation either by interference with platelet function
or other clotting factors. Are there any questions?
From the Audience. Does the thrombocytopenia always appear at the same time
as the circulating anticoagulant in SLE?
Dr. Van Slyck. No, the presence of the anticoagulant may antedate the thrombocytopenia or vice versa. There doesn't seem to be an interrelation, although they
commonly occur together.
Addendum: Mr. K. was given 60 mg of prednisone daily. Follow-up coagulation
studies after one week showed significant improvement in the abnormalities produced
by both the anticoagulant and the thrombocytopenia. Platelet counts increased steadily
to 100,000 per mm' on the seventeenth day after instituting corticosteroid therapy.
Prednisone was then reduced stepwise to 30 mg daily, and the platelet count after
another 14 days was 137,000 per m m l Mr. K. is back at work and feeling well.
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